COMP <GO>
SUPN vs UNH // RETURN ON INVESTED CAPITAL (ROIC)
Supernus Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: SUPN 4
— UNH 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: UNH
LAST: $41.92 (+0.19%) • MKT CAP: $2.44B
roic
-4.50%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
roic
12.38%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SUPN VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SUPN | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.60% | 88.31% | +1.29 | SUPN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -4.50% | 12.38% | -16.88 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.89% | 6.25% | -4.36 | UNH | /fcf-yield <GO> |
| Operating Margin | -8.70% | 5.32% | -14.02 | UNH | /operating-margins <GO> |
| Net Profit Margin | -5.40% | 3.53% | -8.93 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 8.60% | 3.33% | +5.27 | SUPN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.84 | 3.09 | +1.75 | SUPN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.1 | 55.1 | -4.00 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.33 | +0.55 | SUPN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 17.7x | +4.26 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.44B | $359.43B | -$356.99B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SUPN REV | UNH REV | SUPN GROSS % | UNH GROSS % | SUPN FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $719.0M | $447.57B | 89.6% | 88.7% | $46.0M | $16.07B |
| FY 2024 | $661.8M | $400.28B | 88.2% | 88.3% | $171.2M | $20.70B |
| FY 2023 | $607.5M | $371.62B | — | 89.6% | $83.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SUPN // BETA 0.88
UNH // BETA 0.33